The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

opxbiotechnologies.com

Founded Year

2007

Stage

Acquired | Acquired

Total Raised

$64.9M

About OPX Biotechnologies

OPX Biotechnologies develops and produces bio-based chemicals and fuels. The OPX EDGE (Efficiency Directed Genome Engineering) technology platform enables the optimization of microbes and bioprocesses to manufacture bioproducts.

OPX Biotechnologies Headquarter Location

2425 55th Street Suite 100

Boulder, Colorado, 80301,

United States

303-243-5190

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OPX Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OPX Biotechnologies is included in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

OPX Biotechnologies Patents

OPX Biotechnologies has filed 23 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/18/2014

7/2/2019

EC 2.3.1, Molecular biology, Fatty acids, Metabolism, Biotechnology

Grant

Application Date

7/18/2014

Grant Date

7/2/2019

Title

Related Topics

EC 2.3.1, Molecular biology, Fatty acids, Metabolism, Biotechnology

Status

Grant

Latest OPX Biotechnologies News

Panel: Companies’ Big Bets Suggest Cleantech Is Here to Stay

Apr 20, 2017

Reprints For a cleantech startup, it can make sense to fuel growth with venture capital dollars—but only up to a certain point, said Hans Liao. That was one lesson Liao learned after he left Minnesota-based Cargill, the largest private company in the U.S., and in 2009 began working at Boulder, CO-based OPX Biotechnologies, a developer of bio-based acrylic acids and other compounds. He was one member of a panel discussion titled “Translating cleantech from bench to business and back” that was held on Tuesday in Madison, WI. The topics discussed included how early-stage companies can work with larger, more established businesses; how cleantech investment in the U.S. compares to other countries; and what effect the rise of electric vehicles might have on efforts to develop and commercialize technologies that use renewable energy sources. After Liao joined OPX Bio, the startup continued to raise money from venture capital funds, including a $36.5 million funding round in 2011 . But eventually, OPX arrived at a crossroads. One option was seeking the funding to build its own manufacturing plant, Liao said, which was likely to cost hundreds of millions of dollars. It would have also required financial backers to wait years, if not decades, before seeing a return on their investment, he added. That route didn’t have a lot of appeal to the VC firms that had funded OPX up to that point, Liao said. “We were at a point when the venture people just said, ‘We can’t put in any more money, and then have it locked up for 20 years in order to build [a plant],’” he said. So the VC groups began looking for larger organizations—ones with “infrastructure or dollars or market access,” Liao said—and encouraging them to take a closer look at OPX. In 2015, the startup was acquired by none other than Cargill, paving the way for Liao to return to his old employer. (He is currently a senior principal scientist there.) Cargill’s core business is producing and distributing food ingredients and agricultural commodities, such as starches, palm oil, and livestock feed. “In the good old days, you could get money from banks,” Liao said. But over the years, things changed, he said, in part as a result of the financial crisis that hit the U.S. in 2008. “That’s why companies like Cargill exist. We look for strategic partnerships.” Another cleantech startup acquired by a much larger business is Madison, WI-based Virent. The company develops technology aimed at producing cleaner and more sustainable liquid transportation fuels. It’s also working on plant-derived materials that could be used to make everything from plastic bottles to carpeting. Last September, the San Antonio-based petroleum refiner Tesoro (NYSE: TSO ) purchased Virent for an undisclosed sum . Edgar Steenwinkel , vice president of research and development at Virent, said that despite being part of an oil giant, his company’s work on a bio-based paraxylene—a form of the chemical that can be used in packaging containers, fabrics, and other items—isn’t likely to be abandoned entirely. “Our technology is agnostic,” he said. “We can make both [fuels and chemicals]. If you look at how the dynamics are in the industry, there are advantages of developing fuels because there’s … infrastructure around it. [But] there are also advantages with chemicals because people are motivated to buy those [end products].” Tesoro’s acquisition of Virent could be viewed as a signal that the petroleum refiner … Next Page » Single Page Currently on Page: 1 2 Jeff Buchanan is the editor of Xconomy Wisconsin. Email: jbuchanan@xconomy.com Follow @_jeffbuchanan

  • When was OPX Biotechnologies founded?

    OPX Biotechnologies was founded in 2007.

  • Where is OPX Biotechnologies's headquarters?

    OPX Biotechnologies's headquarters is located at 2425 55th Street, Boulder.

  • What is OPX Biotechnologies's latest funding round?

    OPX Biotechnologies's latest funding round is Acquired.

  • How much did OPX Biotechnologies raise?

    OPX Biotechnologies raised a total of $64.9M.

  • Who are the investors of OPX Biotechnologies?

    Investors of OPX Biotechnologies include Cargill, XSeed Capital, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and 5 more.

  • Who are OPX Biotechnologies's competitors?

    Competitors of OPX Biotechnologies include Cathay Industrial Biotech, Akron Biotechnology, Agrivida, Green Biologics, Mendel Biotechnology and 9 more.

You May Also Like

Agrivida Logo
Agrivida

Agrivida is an agricultural biotechnology company developing energy crops designed to produce chemicals, fuels, and bioproducts from non-food cellulosic biomass. The company's approach is designed to provide an integrated solution for delivering the lowest-cost sugars that are essential for industrial bioproducts. The basis of Agrivida's integrated solution is engineering the feedstock to contain cell wall-degrading enzymes, and other valuable traits, which are activated following harvest. Agrivida plans to commercialize its platform through alliances across the bioindustrial product supply chain.

Green Biologics Logo
Green Biologics

Green Biologics is an industrial biotechnology company focused on the production of renewable n-butanol and other C4 chemicals from various renewable feedstocks, including sugar (cane, molasses, beets), starch (corn) and cellulosic biomass (corn residues, sugar cane bagasse, forest materials and grasses). The company works with feedstock partners to deliver capital efficient production models, and works with downstream partners to deliver high quality, competitively priced products. Green Biologics' focus is on the global renewable chemicals and biofuels markets.

E
Excelsyn

Excelsyn integrate specialist management consulting, chemistry and engineering to offer a range of solutions that can enhance performance across the whole pharmaceuticals, biotech and chemicals value chain.

A
Agrisoma BioSciences

Agrisoma Biosciences is an agricultural company that has commercialized carinata, a non-food oilseed crop designed for sustainable production of biofuels. Agrisoma sells carinata seed products under the Resonance brand name, and uses advanced crop improvement technologies to provide superior crop varieties to growers.

Stine Seed Logo
Stine Seed

Stine Seed is an independent seed company dedicated to serving farmer customers with support from its team of agronomists and district and regional managers.

I
Integrated Plant Genetics

Integrated Plant Genetics, Inc. is a development stage biotechnology company, in business to produce and license genes and technologies for the purposes of microbial, horticultural, agricultural and forest tree improvement, including pathogen control. IPG aims to provide contract genetic engineering services, advanced plant breeding technologies for freedom to operate in creating transgenic crops, and assistance in developing regulatory data submission packages. IPG offers environmentally sound and sustainable alternatives to costly and often toxic chemical pest control methods. IPG is a Florida-grown company, with strong ties to the University of Florida, and a commitment to Florida agriculture.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.